{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:56:40Z","timestamp":1786118200157,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ando.2026.102589","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T23:00:14Z","timestamp":1783119614000},"page":"102589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["[18F]F-DOPA and [18F]F-FDG-PET\/CT for staging advanced medullary thyroid cancer"],"prefix":"10.1016","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9687-1497","authenticated-orcid":false,"given":"Sarah","family":"Soueidan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2278-0488","authenticated-orcid":false,"given":"Alexandre","family":"Lugat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Miralli\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Sophie","family":"Delemazure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3417-0759","authenticated-orcid":false,"given":"Francoise","family":"Kraeber Bodere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4579-4129","authenticated-orcid":false,"given":"Delphine","family":"Drui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Ansquer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2026.102589_bib0190","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1056\/NEJM196808082790602","article-title":"Medullary carcinoma of the thyroid gland. Studies of thyrocalcitonin in plasma and tumor extracts","volume":"279","author":"Tashjian","year":"1968","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2026.102589_bib0195","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1210\/jcem-19-1-152","article-title":"Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity","volume":"19","author":"Hazard","year":"1959","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2026.102589_bib0200","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2026.102589_bib0205","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.surg.2016.04.053","article-title":"Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years","volume":"161","author":"Randle","year":"2017","journal-title":"Surgery"},{"key":"10.1016\/j.ando.2026.102589_bib0210","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1365-2265.2004.02037.x","article-title":"Medullary thyroid carcinoma","volume":"61","author":"Leboulleux","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ando.2026.102589_bib0215","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/gut.20.7.629","article-title":"R\u00f4le of calcitonin in diarrhoea associated with medullary carcinoma of the thyroid","volume":"20","author":"Cox","year":"1979","journal-title":"Gut"},{"key":"10.1016\/j.ando.2026.102589_bib0220","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3390\/genes10090698","article-title":"Twenty-five years experience on RET genetic screening on hereditary MTC: an update on the prevalence of germline RET mutations","volume":"10","author":"Elisei","year":"2019","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.ando.2026.102589_bib0225","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1097\/MNM.0000000000001264","article-title":"RET gene mutation analysis and long-term clinical outcomes of medullary thyroid cancer patients","volume":"41","author":"Prabhu","year":"2020","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.ando.2026.102589_bib0230","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1530\/EC-18-0157","article-title":"Incidence and prevalence of sporadic and hereditary MTC in Denmark 1960\u20132014: a nationwide study","volume":"7","author":"Mathiesen","year":"2018","journal-title":"Endocr Connect"},{"key":"10.1016\/j.ando.2026.102589_bib0235","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1210\/jc.2006-1590","article-title":"Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules","volume":"92","author":"Costante","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2026.102589_bib0240","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1056\/NEJM197111112852004","article-title":"Early diagnosis of medullary carcinoma of the thyroid gland by means of calcitonin assay","volume":"285","author":"Melvin","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2026.102589_bib0245","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1210\/jcem.85.2.6556","article-title":"Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d\u2019\u00c9tudes des Tumeurs a Calcitonine (GETC)","volume":"85","author":"Cohen","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2026.102589_bib0250","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/archsurg.142.3.289","article-title":"Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis","volume":"142","author":"Machens","year":"2007","journal-title":"Arch Surg"},{"key":"10.1016\/j.ando.2026.102589_bib0255","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0092-8674(89)90970-7","article-title":"Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule","volume":"57","author":"Benchimol","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.ando.2026.102589_bib0260","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","article-title":"Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"30","author":"Filetti","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ando.2026.102589_bib0265","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1210\/jc.2005-0044","article-title":"Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma","volume":"90","author":"Barbet","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2026.102589_bib0270","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00259-019-04458-6","article-title":"EANM practice guideline for PET\/CT imaging in medullary thyroid carcinoma","volume":"47","author":"Giovanella","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ando.2026.102589_bib0275","first-page":"4078","article-title":"Expression of neuroendocrine cell markers L-dopa decarboxylase, chromogranin A, and dense core granules in human tumors of endocrine and nonendocrine origin","volume":"48","author":"Gazdar","year":"1988","journal-title":"Cancer Res"},{"key":"10.1016\/j.ando.2026.102589_bib0280","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s002590000404","article-title":"18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels","volume":"28","author":"Hoegerle","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.ando.2026.102589_bib0285","doi-asserted-by":"crossref","first-page":"925","DOI":"10.6004\/jnccn.2022.0040","article-title":"Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Haddad","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ando.2026.102589_bib0290","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.2967\/jnumed.116.172221","article-title":"Immuno-PET using anticarcinoembryonic antigen bispecific antibody and 68Ga-labeled peptide in metastatic medullary thyroid carcinoma: clinical optimization of the pretargeting parameters in a first-in-human trial","volume":"57","author":"Bodet-Milin","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ando.2026.102589_bib0295","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1089\/thy.2009.0342","article-title":"Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography\/computed tomography in the follow-up of medullary thyroid carcinoma","volume":"20","author":"Luster","year":"2010","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2026.102589_bib0300","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s00330-008-1280-7","article-title":"The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT","volume":"19","author":"Beheshti","year":"2009","journal-title":"Eur Radiol"},{"key":"10.1016\/j.ando.2026.102589_bib0305","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1007\/s00259-007-0425-2","article-title":"Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma","volume":"34","author":"Beuthien-Baumann","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ando.2026.102589_bib0310","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.2967\/jnumed.111.094771","article-title":"Complementary roles of 18F-DOPA PET\/CT and 18F-FDG PET\/CT in medullary thyroid cancer","volume":"52","author":"Kauhanen","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ando.2026.102589_bib0315","doi-asserted-by":"crossref","first-page":"524","DOI":"10.2967\/jnumed.107.047720","article-title":"18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation","volume":"49","author":"Koopmans","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ando.2026.102589_bib0320","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ejso.2010.01.001","article-title":"Dual PET\/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: comparison with conventional imaging","volume":"36","author":"Marzola","year":"2010","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ando.2026.102589_bib0325","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1007\/s00259-017-3759-4","article-title":"Diagnostic utility of PET\/CT with 18F-DOPA and 18F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff","volume":"44","author":"Romero-Lluch","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ando.2026.102589_bib0330","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00259-011-2031-6","article-title":"Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET\/CT in patients with recurrent medullary thyroid carcinoma","volume":"39","author":"Treglia","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ando.2026.102589_bib0335","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.2967\/jnumed.112.105940","article-title":"Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma","volume":"53","author":"Verbeek","year":"2012","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ando.2026.102589_bib0340","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/cen.12566","article-title":"Role of (18) F-FDOPA PET\/CT imaging in endocrinology","volume":"81","author":"Santhanam","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ando.2026.102589_bib0345","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ando.2026.102589_bib0350","first-page":"328P","article-title":"Positron emission tomography with F-18-fluorodeoxyglucose (PET-FDG) in patients with rapidly progressing medullary thyroid carcinoma (MTC)","volume":"47","author":"Oudoux","year":"2006","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ando.2026.102589_bib0355","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s41824-022-00140-7","article-title":"Early acquisition of [18F]FDOPA PET\/CT imaging in patients with recurrent or residual medullary thyroid cancer is safe-and slightly better!","volume":"6","author":"Kj\u00e6rulff","year":"2022","journal-title":"Eur J Hybrid Imaging"},{"key":"10.1016\/j.ando.2026.102589_bib0360","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1097\/RLU.0000000000002925","article-title":"Which is the optimal scan time of 18F-DOPA PET\/CT in patients with recurrent medullary thyroid carcinoma?: Results from a dynamic acquisition study","volume":"45","author":"Taralli","year":"2020","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.ando.2026.102589_bib0365","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/neuonc\/noz003","article-title":"PET imaging in patients with brain metastasis-report of the RANO\/PET group","volume":"21","author":"Galldiks","year":"2019","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ando.2026.102589_bib0370","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejca.2021.12.005","article-title":"Changing characteristics, treatment approaches and survival of patients with brain metastasis: data from six thousand and thirty-one individuals over an observation period of 30 years","volume":"162","author":"Steindl","year":"2022","journal-title":"Eur J Cancer"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426626001101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426626001101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T15:13:50Z","timestamp":1786029230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426626001101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0003426626001101"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2026.102589","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[18F]F-DOPA and [18F]F-FDG-PET\/CT for staging advanced medullary thyroid cancer","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2026.102589","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"102589"}}